Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday’s trading. The biotech company’s share price was up 8.7% as of 2 p.m. ET despite a 0.8% pullback for the S&P 500 index and a 1.5% decline for the Nasdaq Composite index.
MindMed stock is surging today following a recent report from a Minnesota-based task force that urged the decriminalization of psychedelic mushrooms. The clinical-stage biotech specialist is focused on potential medical applications for psychedelics, and it stands to benefit if restrictions on the category are lessened.
MindMed stock jumps on psychedelic mushroom news
The Minnesota Psychedelic Medicine Task Force published a roughly 200-page report yesterday that supported the decriminalization of psilocybin mushrooms. Two-thirds of the task force voted in favor of recommending decriminalization in Minnesota and the creation of a state-regulated clinical program for administering psilocybin mushrooms as a therapeutic treatment. The task force also called for more funding for research into psychedelics as therapies. If certain legal restrictions on psychedelics were lifted, MindMed could have an easier path to commercializing its treatments.
What comes next for MindMed
MindMed ended the third quarter with cash and equivalents totaling $295.3 million, and management expects that this reserve will be enough to fund the company’s operations into 2027. The business is still in a pre-revenue state, but it announced in December that it had dosed its first patient in it is phase 3 study of lysergide D-tartrate (LSD) as a treatment for generalized anxiety disorder (GAD). The second phase 3 trial for the treatment is expected to begin the first half of this year.
While clinical results will likely be the most significant catalyst in the company’s performance this year, it’s possible that MindMed could get a boost from shifting political dynamics. Robert F. Kennedy Jr. has been nominated by President-elect Donald Trump to be the next Health and Human Services Secretary and has previously voiced support for psychedelics as therapeutic treatments. With phase 3 clinical trials underway and potential political tailwinds on the horizon, MindMed has breakout potential — but investors should approach the stock with the understanding that it’s a risky, speculative play.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
